In:
Pharmaceuticals, MDPI AG, Vol. 15, No. 8 ( 2022-08-10), p. 983-
Abstract:
Bone disorders affect millions of people worldwide and treatments currently available often produce undesirable secondary effects or have limited efficacy. It is therefore of the utmost interest for patients to develop more efficient drugs with reduced off-target activities. In the long process of drug development, screening and preclinical validation have recently gained momentum with the increased use of zebrafish as a model organism to study pathological processes related to human bone disorders, and the development of zebrafish high-throughput screening assays to identify bone anabolic compounds. In this review, we provided a comprehensive overview of the literature on zebrafish bone-related assays and evaluated their performance towards an integration into screening pipelines for the discovery of mineralogenic/osteogenic compounds. Tools available to standardize fish housing and feeding procedures, synchronize embryo production, and automatize specimen sorting and image acquisition/analysis toward faster and more accurate screening outputs were also presented.
Type of Medium:
Online Resource
ISSN:
1424-8247
Language:
English
Publisher:
MDPI AG
Publication Date:
2022
detail.hit.zdb_id:
2193542-7
SSG:
15,3
Permalink
